Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan.
Department of Medical Technology, Chung Hwa University of Medical Technology, Tainan, Taiwan.
Histol Histopathol. 2024 Jan;39(1):91-104. doi: 10.14670/HH-18-615. Epub 2023 Mar 29.
Concurrent chemoradiotherapy (CCRT) is suggested before resection surgery in the control of rectal cancer. Unfortunately, treatment outcomes are widely variable and highly patient-specific. Notably, rectal cancer patients with distant metastasis generally have a much lower survival rate. Accordingly, a better understanding of the genetic background of patient cohorts can aid in predicting CCRT efficacy and clinical outcomes for rectal cancer before distant metastasis.
A published transcriptome dataset (GSE35452) (n=46) was utilized to distinguish prospective genes concerning the response to CCRT. We recruited 172 rectal cancer patients, and the samples were collected during surgical resection after CCRT. Immunohistochemical (IHC) staining was performed to evaluate the expression level of regenerating family member 3 alpha (REG3A). Pearson's chi-squared test appraised the relevance of REG3A protein expression to clinicopathological parameters. The Kaplan-Meier method was utilized to generate survival curves, and the log-rank test was performed to compare the survival distributions between two given groups.
Employing a transcriptome dataset (GSE35452) and focusing on the inflammatory response (GO: 0006954), we recognized that REG3A is the most significantly upregulated gene among CCRT nonresponders (log2 ratio=1.2472, p=0.0079). Following IHC validation, high immunoexpression of REG3A was considerably linked to advanced post-CCRT tumor status (p<0.001), post-CCRT lymph node metastasis (p=0.042), vascular invasion (p=0.028), and low-grade tumor regression (p=0.009). In the multivariate analysis, high immunoexpression of REG3A was independently correlated with poor disease-specific survival (DSS) (p=0.004) and metastasis-free survival (MeFS) (p=0.045). The results of the bioinformatic analysis also supported the idea that REG3A overexpression is implicated in rectal carcinogenesis.
In the current study, we demonstrated that REG3A overexpression is correlated with poor CCRT effectiveness and inferior patient survival in rectal cancer. The predictive and prognostic utility of REG3A expression may direct patient stratification and decision-making more accurately for those patients.
在直肠癌的手术切除前,建议进行同步放化疗(CCRT)。不幸的是,治疗效果差异很大,且高度依赖患者个体情况。值得注意的是,有远处转移的直肠癌患者的生存率通常要低得多。因此,更好地了解患者群体的遗传背景有助于预测直肠癌在远处转移前对 CCRT 的反应和临床结局。
利用已发表的转录组数据集(GSE35452)(n=46)来区分与 CCRT 反应相关的前瞻性基因。我们招募了 172 例直肠癌患者,这些样本是在 CCRT 后手术切除时收集的。通过免疫组织化学(IHC)染色来评估再生家族成员 3α(REG3A)的表达水平。Pearson's chi-squared 检验评估 REG3A 蛋白表达与临床病理参数的相关性。采用 Kaplan-Meier 法生成生存曲线,并采用对数秩检验比较两组之间的生存分布。
利用转录组数据集(GSE35452)并关注炎症反应(GO: 0006954),我们发现 REG3A 是 CCRT 无反应者中表达上调最显著的基因(log2 比值=1.2472,p=0.0079)。通过 IHC 验证,REG3A 的高免疫表达与 CCRT 后肿瘤状态较晚(p<0.001)、CCRT 后淋巴结转移(p=0.042)、血管侵犯(p=0.028)和低级别肿瘤消退(p=0.009)密切相关。在多变量分析中,REG3A 的高免疫表达与疾病特异性生存(DSS)(p=0.004)和无转移生存(MeFS)(p=0.045)不良独立相关。生物信息学分析的结果也支持 REG3A 过表达与直肠癌发生有关的观点。
在本研究中,我们证明了 REG3A 过表达与直肠癌 CCRT 效果不佳和患者生存不良相关。REG3A 表达的预测和预后效用可以更准确地指导患者分层和决策。